Berenberg Keeps UCB at Buy Amid Plan to Maximize Growth of Key Assets

10:05 AM EST, 12/03/2025 (MT Newswires) -- Berenberg on Wednesday noted UCB's (UCB.BR) plan to zero in on maximizing growth opportunities for its psoriasis and anti-inflammatory drug Bimzelx and other key assets in 2026 by implementing smart resource allocation in its US and international markets. At a recent event hosted by the research firm, UCB Chief Financial Officer Sandrine Dufour said the company is also banking on stepping up its digital transformation to help drive topline growth. "Strong Bimzelx growth can support continued margin expansion into next year. For 2026, we forecast 18% sales growth, an EBITDA margin of 34% and 37% EPS growth," analysts said. "Meanwhile, management continues to monitor external opportunities for differentiated assets that complement the UCB portfolio. Focus remains on the earlier stage pipeline, given UCB's existing significant near-mid-term growth drivers." The buy rating on the Belgian biopharmaceutical company's stock and price target of 290 euros were reaffirmed.